Product Description
Bimiralisib is an orally bioavailable pan inhibitor of phosphoinositide-3-kinases (PI3K) and inhibitor of the mammalian target of rapamycin (mTOR), with potential antineoplastic activity. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Bimiralisib)
Mechanisms of Action: PI3K Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Topical
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: PIQUR AG
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Switzerland
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Keratosis, Actinic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| TQR-BTOP-101 | P2 |
Recruiting |
Keratosis, Actinic |
2024-12-01 |